7th PREDiCT: Tumour Models London
  • Park Plaza London Riverbank, 18 Albert Embankment, Greater London, United Kingdom
    SE1 7TJ
  • Tuesday 4th December, 8:00am - Until Thursday 6th December, 5:00pm
Tumour Models London returns for its 7th year and takes a reinvigorated approach towards closing the translational gap between predictable preclinical validation and successful clinical development.

ABOUT THE EVENT:
The PREDiCT Conference Series is dedicated to exploring the latest advances in the application of preclinical models to help us fail faster and get better disease modifying therapies from bench to patient.

Tumour Models London sits at the interface of innovation in model development and therapeutic application.

For the last 7 years it has, and will continue to, bring together a multidisciplinary mix of model developers, translational and pharmacology research scientists to debate how these tools should be further adapted to add immediate value to oncology and IO programmes.

WHY ATTEND?

Merging its unique strategic focus and scientific quality of presentations, the event facilitates an environment of knowledge sharing and debate.
Where other conferences require you sit and listen quietly, we've redesigned the meeting format to ensure interactivity throughout and make sure you'll leave with actionable takeaways on model utility and applicability.

So, whether you're looking to benchmark your model approach or are seeking to explore new systems and technologies, Tumour Models London offers you a unique opportunity to plug into a ready-made network of peers who continue to redefine this area and have already solved the variety of challenges you’re facing.

THE KEY QUESTIONS AT THE HEART OF THE TUMOUR MODELS SERIES:

1. What new model and related technology initiatives are helping biopharma leaders drive translational and early-stage decision making

2. How biopharma leaders are balancing the need for model complexity and relevance with time, throughput and cost

3. What are the key criteria the leading biotech and pharma use to assess, select and characterise the array of tumour models


URLs:
Tickets: https://go.evvnt.com/276973-1?pid=2093
Brochure: https://go.evvnt.com/276973-3?pid=2093
Booking: https://go.evvnt.com/276973-4?pid=2093

Prices:
Drug Developers Pricing: Conference + 2 Workshops: GBP 2999.0,
Drug Developers Pricing: Conference + 1 Workshop: GBP 2599.0,
Drug Developers Pricing: Conference Only: GBP 2199.0,
Model and Service Providers Pricing: Conference + 2 Workshops: GBP 3799.0,
Model and Service Providers Pricing: Conference + 1 Workshop: GBP 3299.0,
Model and Service Providers Pricing: Conference Only: GBP 2799.0

Speakers: Rajendra Kumari General Manager and CSO Crown Bioscience, Ralph Gareus Director Business Development Europe The Jackson Laboratories, Cristina Bertinetti-Lapatki Principal Scientist, Investigative Safety Roche, Dik C. van Gent Associate Professor Erasmus MC, Elizabeth Hardaker Head, Oncology In Vivo Pharmacology Group AstraZeneca, Fabien Garcon Scientist I MedImmune, Gavin Bennett Head of Preclinical Development Bicycle Therapeutics, Giorgio Seano Head of Tumor Microenvironment Lab Institut Curie Research Center, Jayesh Majithiya Senior Scientist Crescendo Biologics, Jean Viallet CEO Inovotion, Markus Reschke Investigator III, Lab Head Oncology Research/Drug Discovery Pharmacology Novartis, Marleen Van Loenen Director - Non-Clinical Development Gadeta, Maryland Franklin Vice President – Scientific Development MI Bioresearch, Anita Seshire Head of Laboratory Cellular Pharmacology and Translational Innovation Platform Oncology Merck KgGA, Ayako Pedersen Head of Translational Research IO Biotech APS, Anne Vaslin Chessex Associate Director, Pharmacology and Screening Debiopharm, Niina Veitonmäki Director In Vivo Immune-Oncology Molecular Partners AG, Alison Mackinnon Preclinical Research Consultant Galecto Biotech

More
Social Interaction
* thebestof cannot be held responsible for any changes, amends or cancellations of an event